Pharmaceutical Company (Alan's Company)

Description

Alan's corporation storms the Roosevelt Room, Alan and Spokesman 2 wielding pricing justifications like weapons—$150/week regimens clash against African wages, donations of free drugs dangled as ethical cover. They shrug off life expectancy unknowns, entrench profit barriers, ignite Toby's fury and Nimbala's pleas. Hierarchy surfaces Alan as lead rep, no brand or execs named; they dictate global access terms, fracturing alliances in the AIDS crisis summit.

Event Involvements

Events with structured involvement data

2 events

S2E4 · In This White House

The Price of Life: Josh Maps Drug Economics

Alan's pharmaceutical company dominates defenses—Norway pricing tiers, Fluconazole/Zyclocint sales/donations, life-expectancy unknowns—via reps' shrugs and data volleys, entrenching profit barriers against Nimbala/Toby/Josh assaults in the pricing inferno.

Active Representation

Through lead rep Alan and Spokesman 2's direct advocacy

Power Dynamics

Defensive stronghold challenged by White House moral/political leverage

Institutional Impact

Exposes IP monopolies throttling global health equity

Organizational Goals

Protect patent-driven pricing models Reframe crisis as African logistics failure

Influence Mechanisms

Tiered pricing justifications Donation tallies as ethical cover

S2E4 · In This White House

Roosevelt Room Breakdown: When Ethics Collide With Cost

Alan's company dominates as pricing antagonist—defending Norway markups, Fluconazole billion-dollar sales, Zyclocint donations, unknown lifespans—erecting profit/logistics barriers against Nimbala's pleas and staff probes, its reps' shrugs precipitating Toby's exit.

Active Representation

Through lead rep Alan and Spokesman 2's verbal defenses

Power Dynamics

Entrenched via patents, challenged by White House moral/political pressure

Institutional Impact

Exposes IP-driven health inequities straining U.S. diplomacy

Organizational Goals

Preserve pricing tiers and IP monopolies Reframe critique onto African distribution failures

Influence Mechanisms

Logistical excuses and donation stats Fatalistic lifespan uncertainties